CEBP:每日服用低剂量阿司匹林可能会降低胰腺癌风险

2016-12-22 佚名 侨报网

一项新出炉的研究显示,每天服用低剂量的阿司匹林可能会降低患胰腺癌的风险。据合众国际社报道,该研究论文主要作者、耶鲁公共卫生学院流行病学教授里施(Harvey Risch)博士表示,来自中国的这项研究虽然并未证明其中的因果关系,然而一些明显证据表明,服用阿司匹林不仅可降低患心血管病或结直肠癌的风险,也有可能会降低人们患胰腺癌的风险。据美国癌症协会统计,今年约有5.3万美国人将被诊断为胰腺癌,每年约4

一项新出炉的研究显示,每天服用低剂量的阿司匹林可能会降低患胰腺癌的风险。

据合众国际社报道,该研究论文主要作者、耶鲁公共卫生学院流行病学教授里施(Harvey Risch)博士表示,来自中国的这项研究虽然并未证明其中的因果关系,然而一些明显证据表明,服用阿司匹林不仅可降低患心血管病或结直肠癌的风险,也有可能会降低人们患胰腺癌的风险。


据美国癌症协会统计,今年约有5.3万美国人将被诊断为胰腺癌,每年约4.2万人死于这种疾病。胰腺癌通常就像一位“沉默杀手”,因为直到肿瘤晚期,患病症状才会出现。

该研究于2006至2011年间对上海761名被诊断为胰腺癌的患者进行了跟踪调查,同时将他们与未患癌症的794名健康人士进行了比较。

所有受访者都被询问是否定期服用了低剂量阿司匹林。研究发现,18%非癌症患者都会定期服用低剂量阿司匹林,而胰腺癌患者仅有11%。研究人员在排除其他各种因素,对统计数据进行调整后发现,阿司匹林可能会降低患胰腺癌风险46%。

里施博士指出,这项研究并未直接证明阿司匹林是导致降低风险的原因,而受访者可能也未准确地记住他们服用阿司匹林的剂量。但其他一些研究也发现了类似的结果。过去18年来,不少研究人员都调查研究了阿司匹林服用与胰腺癌风险间的关系,并发现,随着阿司匹林用量的增加,胰腺癌的风险呈显著降低。

里施在美国癌症研究协会的一个新闻发布会上表示,胰腺癌是相对少见的,美国成人仅有1.5%在某个时候可能被诊断为这一疾病,而且经常服用阿司匹林也会引起明显的并发症,因此,在服用阿司匹林之前应该向医生进行咨询。

对此,纽约州瘤科专家菲利普(Tony Philip)博士认为,美国人应对于来自中国的这一研究结果保持谨慎解释的立场。他指出,世界上任何某一部分人的基因与其他地区可能都有很大的不同,此外,对于该研究受访者的具体情况也并不清除,包括他们是否服用了中药,是否有家族病史等。

他表示,他本人不会建议病人每天服用低剂量阿司匹林,但这项研究结果可以作为进一步进行论证的基础。

该研究发表在12月20日的《癌症流行病学、生物指标及预防》(Cancer Epidemiology, Biomarkers & Prevention)上。

原始出处:

Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao YT. Aspirin Use and Reduced Risk of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev. 2016 Dec 20. doi: 10.1158/1055-9965.EPI-16-0508

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-24 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-26 大爰

    再次学习并分享感谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-25 大爰

    再次学习并分享感谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-24 大爰

    学习了增加知识了分享了谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-23 大爰

    继续学习并分享感谢

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-23 doctorJiangchao

    继续学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2007449, encodeId=e719200e44999, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Tue Feb 21 06:48:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061591, encodeId=5b8220615916e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Dec 24 11:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165738, encodeId=1d01165e38a3, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Dec 26 08:56:37 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165474, encodeId=59d21654e448, content=再次学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Dec 25 06:59:25 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165292, encodeId=5e89165292b9, content=学习了增加知识了分享了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Dec 24 08:41:13 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480433, encodeId=2e0c14804337d, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Dec 24 06:48:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165062, encodeId=40c9165062c1, content=继续学习并分享感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Dec 23 08:56:07 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164976, encodeId=c5c81649e648, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Dec 23 00:11:13 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164913, encodeId=495e16491307, content=阿司匹林世上最伟大的药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Thu Dec 22 16:31:10 CST 2016, time=2016-12-22, status=1, ipAttribution=)]
    2016-12-22 杨帆7792

    阿司匹林世上最伟大的药物

    0

相关资讯

阿司匹林可以有效减缓结肠癌和胰腺肿瘤细胞的生长

来自俄勒冈健康科学大学和俄勒冈州立大学的研究人员发现,阿司匹林可以减缓某些类型的结肠和胰腺癌细胞的传播。该论文发表在美国生理学杂志--“细胞生理学”上。 血小板是与凝血有关的血细胞。它们通过释放生长因子并增加调节肿瘤细胞发育的某些蛋白质(癌蛋白)的应答来促进癌细胞的生长。低剂量的阿司匹林--一种抗血小板药物,已显示能够降低某些类型的胃肠癌的风险,但阿司匹林阻碍肿瘤生长的过程尚不清楚。研究人员

AJPCP:阿司匹林也可抑制结肠癌和前列腺癌生长?

来自俄勒冈卫生科学大学的研究人员发现阿司匹林居然可以抑制某些结肠癌和前列腺癌转移,相关研究成果最近发表在《美国生理学杂志——细胞生理学》上。 血小板是一种参与凝血的血细胞,它们也可以通过释放生长因子和增强肿瘤蛋白表达而促进肿瘤细胞生长。作为一种抗血小板药物,研究人员早已发现低剂量的阿司匹林可以降低某些肿瘤的生长,但是其中的机理并不清楚。这项最新的研究就是为了确定阿司匹林抑制血小板激活对结肠癌

必看:2017版NCCN结直肠癌指南的更新!

导语: 2016年11月23日,NCCN在线发布了2017版结肠癌和直肠癌临床实践指南,和2016年V2版对比,还是出现了很多能改变临床实践的更新,尤其关于左右半的问题,由于以指南的形式第一次推荐将原发瘤部位纳入mCRC一线治疗中靶向药物的选择参考依据,这必将是里程碑式的更新,相信也会是引起轩然大波的更新。以下是笔者对2017版NCCN结直肠癌指南的可能会改变临床实践的主要更新做一解读,不看不

长时间使用止痛剂可增加听力损失的风险

近日,来自哈佛医学院和波士顿妇女医院的研究人员发现,使用对乙酰氨基酚或非甾体类抗炎药如布洛芬6年及以上的女性来说,其听力丧失的风险较未使用如此长时间的女性高,其研究成果已发表于American Journal of Epidemiology。研究人员使用了55850名参加护士健康研究的女性的数据,分析这些女性自述的听力损失与其使用布洛芬、对乙酰氨基酚和阿司匹林之间的联系。结果表明,长期使用(持续6

新证据!阿司匹林可减缓结肠癌、胰腺癌细胞扩散

导语:先前的研究发现低剂量的阿司匹林能够降低某些类型胃肠道癌症的风险。但阿司匹林阻碍肿瘤生长的机制一直仍不清楚。近日,科学家们证实,阿司匹林减缓结肠癌和胰腺癌细胞扩散的作用与血小板有关。11月30日,发表在American Journal of Physiology - Cell Physiology上的一项研究中,来自俄勒冈健康与科学大学(Oregon Health and science un

阿司匹林到底何时服?

导读:阿司匹林肠溶片,晨起空腹服用效果最好;普通剂型,仍应在早餐后服用,减轻药物副作用。阿司匹林是临床应用最为广泛的药物之一。除具有良好的解热镇痛作用外,还具有抑制血小板激活和抗血栓形成的良好作用,可用作冠心病和脑血管病的一级、二级预防,对防范和减少冠心病急性事件及缺血性脑卒中的发生、发展意义重大。那么阿司匹林何时服用才是正确的呢?餐前OR餐后?餐前理论阿司匹林口服可对胃部造成强烈刺激 , 加上阿